Arid1a deficiency sensitises pancreatic cancer to fatty acid synthase inhibition
ARID1A mutations drive metabolic reprogramming in pancreatic cancer. Co-occurrence of K-ras mutation and Arid1a loss induces tumor formation with distinct immune microenvironment features. FASN is upregulated by ARID1A deficiency and its inhibition suppresses tumor growth. Targeting FASN may benefit patients with ARID1A-deficient pancreatic cancer.
Authors
- Ya‐Chin Hou (ORCID: https://orcid.org/0000-0001-9918-9568)
- Yan‐Shen Shan (ORCID: https://orcid.org/0000-0002-2457-5189)
- Tzu‐Lei Kuo (ORCID: https://orcid.org/0009-0004-1650-493X)
- Wen‐Chun Hung (ORCID: https://orcid.org/0000-0003-4860-5415)
- Li‐Tzong Chen (ORCID: https://orcid.org/0000-0003-3250-7167)
Institutions
- National Yang Ming Chiao Tung University (TW)
- Kaohsiung Medical University (TW)
- National Health Research Institutes (TW)
- Kaohsiung Medical University Chung-Ho Memorial Hospital (TW)
- National Cheng Kung University Hospital (TW)
- National Cheng Kung University (TW)
Publication Details
- Journal
- Clinical and Translational Medicine
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1002/ctm2.70394
- Citations
- 1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05